The DOI matches its Crossref record; 305 of the 305 references it cites were found in a registry or an index.
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Open accessAbstract
Diabetic nephropathy (DN) is associated with an increased morbidity and mortality, resulting in elevated cost for public health systems. DN is the main cause of chronic kidney disease (CKD) and its incidence increases the number of patients that develop the end-stage renal disease (ESRD). There are growing epidemiological and preclinical evidence about the close relationship between inflammatory response and the occurrence and progression of DN. Several anti-inflammatory strategies targeting specific inflammatory mediators (cell adhesion molecules, chemokines and cytokines) and intracellular signaling pathways have shown beneficial effects in experimental models of DN, decreasing proteinuria and renal lesions. A number of inflammatory molecules have been shown useful to identify diabetic patients at high risk of developing renal complications. In this review, we focus on the key role of inflammation in the genesis and progression of DN, with a special interest in effector molecules and activated intracellular pathways leading to renal damage, as well as a comprehensive update of new therapeutic strategies targeting inflammation to prevent and/or retard renal injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Activation and regulation of the inflammasomes
Latz, E., Xiao, T. S., & Stutz, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3452 · Cited by 2,884
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Esposito, K., Nappo, F., Marfella, R., Giugliano, G., Giugliano, F., Ciotola, M., Quagliaro, L., Ceriello, A., & Giugliano, D. (2002) · Circulation · doi:10.1161/01.cir.0000034509.14906.ae · Cited by 1,961 · cited 1×
“Studies in patients have demonstrated that glucose administration increased IL-6 or IL-18 plasma concentration, an effect that was reduced with the antioxidant glutathione [27].”
BackgroundInterleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
The PI3K/AKT Pathway in Obesity and Type 2 Diabetes
Huang, X., Liu, G., Guo, J., & Su, Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27173 · Cited by 1,673
The JAK-STAT Pathway at Twenty
Stark, G. R., & Darnell, J. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.013 · Cited by 1,517
The IL-1 family: regulators of immunity
Sims, J. E., & Smith, D. E. (2010) · Nature Reviews Immunology · doi:10.1038/nri2691 · Cited by 1,418
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Meyer, M., Schreck, R., & Baeuerle, P. A. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05850.x · Cited by 1,313
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Mechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306033 · Cited by 1,030
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505066 · Cited by 1,029
The molecular details of cytokine signaling via the JAK/STAT pathway
Morris, R., Kershaw, N. J., & Babon, J. J. (2018) · Protein Science · doi:10.1002/pro.3519 · Cited by 943
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
The Role of Inflammatory Cytokines in Diabetic Nephropathy
Navarro-González, J. F., & Mora-Fernández, C. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007091048 · Cited by 932
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Macrophage diversity in renal injury and repair
Ricardo, S. D., van Goor, H., & Eddy, A. A. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36150 · Cited by 724
Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease
Cachofeiro, V., Goicochea, M., de Vinuesa, S. G., Oubiña, P., Lahera, V., & Luño, J. (2008) · Kidney International · doi:10.1038/ki.2008.516 · Cited by 662
Stehouwer, C. D. A., Gall, M.-A., Twisk, J. W. R., Knudsen, E., Emeis, J. J., & Parving, H.-H. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1157 · Cited by 652
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Relationship between Oxidative Stress and Inflammatory Cytokines in Diabetic Nephropathy
Elmarakby, A. A., & Sullivan, J. C. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00218.x · Cited by 641
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Thomas, S. J., Snowden, J. A., Zeidler, M. P., & Danson, S. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.233 · Cited by 637
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Pathogenetic Mechanisms of Diabetic Nephropathy
Schena, F. P., & Gesualdo, L. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110970 · Cited by 589
Chow, F., Ozols, E., Nikolic-Paterson, D. J., Atkins, R. C., & Tesch, G. H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00367.x · Cited by 551
Blumberg, H., Conklin, D., Xu, W., Grossmann, A., Brender, T., Carollo, S., Eagan, M., Foster, D., Haldeman, B. A., Hammond, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00187-8 · Cited by 547
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538
Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes
Niewczas, M. A., Gohda, T., Skupien, J., Smiles, A. M., Walker, W. H., Rosetti, F., Cullere, X., Eckfeldt, J. H., Doria, A., Mayadas, T. N., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060627 · Cited by 485
NOD-Like Receptors in Infection, Immunity, and Diseases
Kim, Y. K., Shin, J.-S., & Nahm, M. H. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.1.5 · Cited by 463
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation?
Wen, H., Ting, J. P.-Y., & O'Neill, L. A. J. (2012) · Nature Immunology · doi:10.1038/ni.2228 · Cited by 457
Chow, F. Y., Nikolic-Paterson, D. J., Ozols, E., Atkins, R. C., Rollin, B. J., & Tesch, G. H. (2006) · Kidney International · doi:10.1038/sj.ki.5000014 · Cited by 440
Niewczas, M. A., Pavkov, M. E., Skupien, J., Smiles, A., Md Dom, Z. I., Wilson, J. M., Park, J., Nair, V., Schlafly, A., Saulnier, P.-J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0415-5 · Cited by 432
Innate immunity in diabetes and diabetic nephropathy
Wada, J., & Makino, H. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.175 · Cited by 427
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy
Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., Brunner, B., Eichinger, F., Nitsche, A., Kiss, E., Bleich, M., Gröne, H.-J., et al. (2006) · Diabetes · doi:10.2337/db06-0477 · Cited by 419
NF- B activation and overexpression of regulated genes in human diabetic nephropathy
Mezzano, S., Aros, C., Droguett, A., Burgos, M. E., Ardiles, L., Flores, C., Schneider, H., Ruiz-Ortega, M., & Egido, J. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh207 · Cited by 381
Self-citationEarly events leading to renal injury in obese Zucker (fatty) rats with type II diabetes
Coimbra, T. M., Janssen, U., Gröne, H. J., Ostendorf, T., Kunter, U., Schmidt, H., Brabant, G., & Floege, J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00836.x · Cited by 377
NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes
Suryavanshi, S. V., & Kulkarni, Y. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00798 · Cited by 348
Leukocyte – endothelial interactions in inflammation
Langer, H. F., & Chavakis, T. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00811.x · Cited by 344
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341
Macrophage accumulation in human progressive diabetic nephropathy
NGUYEN, D., PING, F., MU, W., HILL, P., ATKINS, R. C., & CHADBAN, S. J. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00576.x · Cited by 331
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Everett, B. M., Donath, M. Y., Pradhan, A. D., Thuren, T., Pais, P., Nicolau, J. C., Glynn, R. J., Libby, P., & Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.002 · Cited by 329
Eller, K., Kirsch, A., Wolf, A. M., Sopper, S., Tagwerker, A., Stanzl, U., Wolf, D., Patsch, W., Rosenkranz, A. R., & Eller, P. (2011) · Diabetes · doi:10.2337/db11-0358 · Cited by 318
Berthier, C. C., Zhang, H., Schin, M., Henger, A., Nelson, R. G., Yee, B., Boucherot, A., Neusser, M. A., Cohen, C. D., Carter-Su, C., et al. (2009) · Diabetes · doi:10.2337/db08-1328 · Cited by 317
Mease, P., van der Heijde, D., Landewé, R., Mpofu, S., Rahman, P., Tahir, H., Singhal, A., Boettcher, E., Navarra, S., Meiser, K., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212687 · Cited by 303
Okada, S., Shikata, K., Matsuda, M., Ogawa, D., Usui, H., Kido, Y., Nagase, R., Wada, J., Shikata, Y., & Makino, H. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2586 · Cited by 298
Pichler, R., Afkarian, M., Dieter, B. P., & Tuttle, K. R. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00314.2016 · Cited by 295
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Cavelti-Weder, C., Babians-Brunner, A., Keller, C., Stahel, M. A., Kurz-Levin, M., Zayed, H., Solinger, A. M., Mandrup-Poulsen, T., Dinarello, C. A., & Donath, M. Y. (2012) · Diabetes Care · doi:10.2337/dc11-2219 · Cited by 294
Tuttle, K. R., Brosius, F. C., Adler, S. G., Kretzler, M., Mehta, R. L., Tumlin, J. A., Tanaka, Y., Haneda, M., Liu, J., Silk, M. E., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx377 · Cited by 284
Han, J. H., Oh, T. J., Lee, G., Maeng, H. J., Lee, D. H., Kim, K. M., Choi, S. H., Jang, H. C., Lee, H. S., Park, K. S., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4158-2 · Cited by 281
The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
Lieberthal, W., & Levine, J. S. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111186 · Cited by 280
de Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni-Berthold, I., Mehling, H., Potarca, A., Tesar, V., Heerspink, H. J. L., & Schall, T. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00261-2 · Cited by 273
Moriwaki, Y., Yamamoto, T., Shibutani, Y., Aoki, E., Tsutsumi, Z., Takahashi, S., Okamura, H., Koga, M., Fukuchi, M., & Hada, T. (2003) · Metabolism · doi:10.1053/meta.2003.50096 · Cited by 270
Chung, A. C. K., & Lan, H. Y. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010050510 · Cited by 268
Evidence of IL-18 as a Novel Angiogenic Mediator
Park, C. C., Morel, J. C. M., Amin, M. A., Connors, M. A., Harlow, L. A., & Koch, A. E. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1644 · Cited by 263
SOCS, Inflammation, and Autoimmunity
Yoshimura, A., Suzuki, M., Sakaguchi, R., Hanada, T., & Yasukawa, H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00020 · Cited by 254
Chow, F. Y., Nikolic-Paterson, D. J., Ma, F. Y., Ozols, E., Rollins, B. J., & Tesch, G. H. (2007) · Diabetologia · doi:10.1007/s00125-006-0497-8 · Cited by 250
Sucosky, P., Balachandran, K., Elhammali, A., Jo, H., & Yoganathan, A. P. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.176347 · Cited by 235
Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD
Pergola, P. E., Krauth, M., Huff, J. W., Ferguson, D. A., Ruiz, S., Meyer, C. J., & Warnock, D. G. (2011) · American Journal of Nephrology · doi:10.1159/000327599 · Cited by 233
Diabetic nephropathy: Is there a role for oxidative stress?
Sagoo, M. K., & Gnudi, L. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.12.040 · Cited by 233
Hendarto, H., Inoguchi, T., Maeda, Y., Ikeda, N., Zheng, J., Takei, R., Yokomizo, H., Hirata, E., Sonoda, N., & Takayanagi, R. (2012) · Metabolism · doi:10.1016/j.metabol.2012.03.002 · Cited by 232
Wang, C., Pan, Y., Zhang, Q.-Y., Wang, F.-M., & Kong, L.-D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038285 · Cited by 232
Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes
Porrini, E., Ruggenenti, P., Mogensen, C. E., Barlovic, D. P., Praga, M., Cruzado, J. M., Hojs, R., Abbate, M., & de Vries, A. P. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00094-7 · Cited by 232
Navarro-González, J. F., Mora-Fernández, C., Muros de Fuentes, M., Chahin, J., Méndez, M. L., Gallego, E., Macía, M., del Castillo, N., Rivero, A., Getino, M. A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010012 · Cited by 221
Lemos, D. R., McMurdo, M., Karaca, G., Wilflingseder, J., Leaf, I. A., Gupta, N., Miyoshi, T., Susa, K., Johnson, B. G., Soliman, K., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121283 · Cited by 220
Role of the JAK/STAT signaling pathway in diabetic nephropathy
Marrero, M. B., Banes-Berceli, A. K., Stern, D. M., & Eaton, D. C. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00181.2005 · Cited by 219
Nakamura, A., Shikata, K., Hiramatsu, M., Nakatou, T., Kitamura, T., Wada, J., Itoshima, T., & Makino, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2890 · Cited by 218
Role of Transcription Factor Acetylation in Diabetic Kidney Disease
Liu, R., Zhong, Y., Li, X., Chen, H., Jim, B., Zhou, M.-M., Chuang, P. Y., & He, J. C. (2014) · Diabetes · doi:10.2337/db13-1810 · Cited by 216
Attenuation of diabetic nephropathy by tocotrienol: Involvement of NFkB signaling pathway
Kuhad, A., & Chopra, K. (2009) · Life Sciences · doi:10.1016/j.lfs.2008.12.014 · Cited by 205
Nrf2 Protects Pancreatic β-Cells From Oxidative and Nitrosative Stress in Diabetic Model Mice
Yagishita, Y., Fukutomi, T., Sugawara, A., Kawamura, H., Takahashi, T., Pi, J., Uruno, A., & Yamamoto, M. (2014) · Diabetes · doi:10.2337/db13-0909 · Cited by 204
Menne, J., Eulberg, D., Beyer, D., Baumann, M., Saudek, F., Valkusz, Z., Więcek, A., Haller, H., & for the Emapticap Study Group (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv459 · Cited by 201
Dendritic cells and macrophages in the kidney: a spectrum of good and evil
Rogers, N. M., Ferenbach, D. A., Isenberg, J. S., Thomson, A. W., & Hughes, J. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.170 · Cited by 199
The role of TNF-α in diabetic nephropathy: Pathogenic and therapeutic implications
NAVARRO, J., & MORAFERNANDEZ, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.09.011 · Cited by 198
Pieper, G. M., & Riaz-ul-Haq (1997) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199710000-00019 · Cited by 198
NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice
Wu, M., Han, W., Song, S., Du, Y., Liu, C., Chen, N., Wu, H., Shi, Y., & Duan, H. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.08.002 · Cited by 197
Adhikary, L., Chow, F., Nikolic-Paterson, D. J., Stambe, C., Dowling, J., Atkins, R. C., & Tesch, G. H. (2004) · Diabetologia · doi:10.1007/s00125-004-1437-0 · Cited by 195
Cytokines and vascular reactivity in resistance arteries
Vila, E., & Salaices, M. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00779.2004 · Cited by 194
Sugimoto, H., Shikata, K., Hirata, K., Akiyama, K., Matsuda, M., Kushiro, M., Shikata, Y., Miyatake, N., Miyasaka, M., & Makino, H. (1997) · Diabetes · doi:10.2337/diab.46.12.2075 · Cited by 193
Ohshiro, Y., Ma, R. C., Yasuda, Y., Hiraoka-Yamamoto, J., Clermont, A. C., Isshiki, K., Yagi, K., Arikawa, E., Kern, T. S., & King, G. L. (2006) · Diabetes · doi:10.2337/db06-0895 · Cited by 188
mTOR pathway as a target in tissue hypertrophy
Lee, C.-H., Inoki, K., & Guan, K.-L. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105359 · Cited by 179
Suppressors of Cytokine Signaling Abrogate Diabetic Nephropathy
Ortiz-Muñoz, G., Lopez-Parra, V., Lopez-Franco, O., Fernandez-Vizarra, P., Mallavia, B., Flores, C., Sanz, A., Blanco, J., Mezzano, S., Ortiz, A., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060625 · Cited by 178
Self-citationThe glycocalyx—linking albuminuria with renal and cardiovascular disease
Rabelink, T. J., & de Zeeuw, D. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.162 · Cited by 178
Rapamycin Prevents Early Steps of the Development of Diabetic Nephropathy in Rats
Yang, Y., Wang, J., Qin, L., Shou, Z., Zhao, J., Wang, H., Chen, Y., & Chen, J. (2007) · American Journal of Nephrology · doi:10.1159/000106782 · Cited by 174
Potential Role of Serum and Urinary Biomarkers in Diagnosis and Prognosis of Diabetic Nephropathy
Campion, C. G., Sanchez-Ferras, O., & Batchu, S. N. (2017) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358117705371 · Cited by 170
Targeting inflammation in diabetic nephropathy: a tale of hope
Moreno, J. A., Gomez-Guerrero, C., Mas, S., Sanz, A. B., Lorenzo, O., Ruiz-Ortega, M., Opazo, L., Mezzano, S., & Egido, J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1538352 · Cited by 170
Self-citationZheng, C., Huang, L., Luo, W., Yu, W., Hu, X., Guan, X., Cai, Y., Zou, C., Yin, H., Xu, Z., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2085-0 · Cited by 170
Inflammation in diabetic kidney disease
García-García, P. M., Getino-Melián, M. A., Domínguez-Pimentel, V., & Navarro-González, J. F. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i4.431 · Cited by 168
The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications
Herder, C., Dalmas, E., Böni-Schnetzler, M., & Donath, M. Y. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.08.001 · Cited by 168
Goldszmid, R. S., & Trinchieri, G. (2012) · Nature Immunology · doi:10.1038/ni.2422 · Cited by 166
Sayyed, S. G., Hägele, H., Kulkarni, O. P., Endlich, K., Segerer, S., Eulberg, D., Klussmann, S., & Anders, H.-J. (2009) · Diabetologia · doi:10.1007/s00125-009-1493-6 · Cited by 166
Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy
Kanamori, H., Matsubara, T., Mima, A., Sumi, E., Nagai, K., Takahashi, T., Abe, H., Iehara, N., Fukatsu, A., Okamoto, H., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.148 · Cited by 166
Macrophages directly mediate diabetic renal injury
You, H., Gao, T., Cooper, T. K., Brian Reeves, W., & Awad, A. S. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00141.2013 · Cited by 166
Chin, M. P., Bakris, G. L., Block, G. A., Chertow, G. M., Goldsberry, A., Inker, L. A., Heerspink, H. J. L., O’Grady, M., Pergola, P. E., Wanner, C., et al. (2018) · American Journal of Nephrology · doi:10.1159/000486398 · Cited by 165
Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice
Kim, J. E., Lee, M., Nam, D. H., Song, H. K., Kang, Y. S., Lee, J. E., Kim, H. W., Joo, J., Hyun, Y. Y., Han, S. Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062068 · Cited by 163
Aberrant Recruitment and Activation of T Cells in Diabetic Nephropathy
Moon, J.-Y., Jeong, K.-H., Lee, T.-W., Ihm, C.-G., Lim, S. J., & Lee, S.-H. (2012) · American Journal of Nephrology · doi:10.1159/000334928 · Cited by 161
Ikezumi, Y., Hurst, L., Masaki, T., Atkins, R. C., & Nikolic‐Paterson, D. J. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00717.x · Cited by 157
Immune Cells and Inflammation in Diabetic Nephropathy
Zheng, Z., & Zheng, F. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1841690 · Cited by 157
Jiménez‐Osorio, A. S., García‐Niño, W. R., González-Reyes, S., Álvarez-Mejía, A. E., Guerra-León, S., Salazar-Segovia, J., Falcón, I., de Oca-Solano, H. M., Madero, M., & Pedraza‐Chaverrí, J. (2016) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2016.01.013 · Cited by 157
Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics
Wolkow, P. P., Niewczas, M. A., Perkins, B., Ficociello, L. H., Lipinski, B., Warram, J. H., & Krolewski, A. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050556 · Cited by 155
Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes
DiPetrillo, K., Coutermarsh, B., & Gesek, F. A. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00026.2002 · Cited by 154
Cheon, H., Yang, J. B., & Stark, G. R. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0100 · Cited by 153
Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway
Chen, Y., Kong, L., Tang, Z., Zhang, Y., Liu, Y., Wang, T., & Liu, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.01.030 · Cited by 150
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies
Drechsler, C., Delgado, G., Wanner, C., Blouin, K., Pilz, S., Tomaschitz, A., Kleber, M. E., Dressel, A., Willmes, C., Krane, V., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010093 · Cited by 149
Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy
Luis-Rodríguez, D., Martínez‐Castelao, A., Górriz, J. L., De-Álvaro, F., & Navarro‐González, J. F. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i1.7 · Cited by 148
Du, P., Han, H., Han, H., Zhen, J., Shang, J., Wang, X., Li, X., Shi, W., Tang, W., Bao, C., et al. (2013) · Kidney International · doi:10.1038/ki.2013.113 · Cited by 148
Effects of Interleukin 17 on the cardiovascular system
Robert, M., & Miossec, P. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.009 · Cited by 147
ASK1 contributes to fibrosis and dysfunction in models of kidney disease
Liles, J. T., Corkey, B. K., Notte, G. T., Budas, G. R., Lansdon, E. B., Hinojosa-Kirschenbaum, F., Badal, S. S., Lee, M., Schultz, B. E., Wise, S. J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99768 · Cited by 147
JAK inhibition in the treatment of diabetic kidney disease
Brosius, F. C., Tuttle, K. R., & Kretzler, M. (2016) · Diabetologia · doi:10.1007/s00125-016-4021-5 · Cited by 145
Navarro‐González, J. F., Milena, F. F., Mora, C., León, C., Claveríe‐Martín, F., Flores, C. G., & García, J. G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09918.x · Cited by 144
Navarro‐González, J. F., Fernández, C. M., Rivero, A., Gallego, E., Chahin, J., Macia, M. L., Méndez, M. L., & García, J. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70182-4 · Cited by 143
Investigating Evolutionary Conservation of Dendritic Cell Subset Identity and Functions
Manh, T. V., Bertho, N., Hosmalin, A., Schwartz-Cornil, I., & Dalod, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00260 · Cited by 143
Cui, W., Bai, Y., Miao, X., Luo, P., Chen, Q., Tan, Y., Rane, M. J., Miao, L., & Cai, L. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/821936 · Cited by 141
Song, N., Thaiss, F., & Guo, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00815 · Cited by 141
Galectin-3: an emerging all-out player in metabolic disorders and their complications
Pugliese, G., Iacobini, C., Pesce, C. M., & Menini, S. (2014) · Glycobiology · doi:10.1093/glycob/cwu111 · Cited by 137
Peng, X., Xiao, Z., Zhang, J., Li, Y., Dong, Y., & Du, J. (2014) · The Journal of Pathology · doi:10.1002/path.4430 · Cited by 137
Ahmed, S., Mundhe, N., Borgohain, M. P., Chowdhury, L., Kwatra, M., Bolshette, N. B., Ahmed, A., & Lahkar, M. (2016) · Inflammation · doi:10.1007/s10753-016-0413-4 · Cited by 137
Lee, E. Y., Chung, C. H., Khoury, C. C., Yeo, T. K., Pyagay, P. E., Wang, A., & Chen, S. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90642.2008 · Cited by 135
Samra, Y. A., Said, H. S., Elsherbiny, N. M., Liou, G. I., El‐Shishtawy, M. M., & Eissa, L. A. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.06.002 · Cited by 135
The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy
Lin, M. Y., Yiu, W. H., Li, R. X., Wu, H., Wong, D. W. L., Chan, L. Y. Y., Leung, J. C. K., Lai, K. N., & Tang, S. C. W. (2013) · Kidney International · doi:10.1038/ki.2013.11 · Cited by 132
Mohamed, R., Jayakumar, C., Chen, F., Fulton, D. J., Stepp, D. W., Gansevoort, R. T., & Ramesh, G. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111136 · Cited by 131
Caspase-1, but Not Caspase-3, Promotes Diabetic Nephropathy
Shahzad, K., Bock, F. M., Al‐Dabet, M. M., Gadi, I., Kohli, S., Nazir, S., Ghosh, S. P., Ranjan, S., Wang, H., Madhusudhan, T., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060676 · Cited by 131
Expression of Gremlin, a Bone Morphogenetic Protein Antagonist, in Human Diabetic Nephropathy
Dolan, V., Murphy, M., Sadlier, D. M., Lappin, D. W. P., Doran, P., Godson, C., Martin, F., O’Meara, Y., Schmid, H., Henger, A., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.03.014 · Cited by 129
Self-citationThe Role of chemokines and chemokine receptors in diabetic nephropathy
Rüster, C. (2007) · Frontiers in bioscience · doi:10.2741/2734 · Cited by 126
Sun, Y., Peng, R., Peng, H., Liu, H., Wen, L., Wu, T., Yi, H. L., Li, A., & Zhang, Z. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.06.004 · Cited by 126
Zhang, C., Zhu, X., Li, L., Ma, T., Shi, M., Yang, Y., & Fan, Q. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s199802 · Cited by 126
Suppressors of Cytokine Signaling Modulate JAK/STAT-Mediated Cell Responses During Atherosclerosis
Ortiz-Muñoz, G., Martín-Ventura, J. L., Hernández-Vargas, P., Mallavia, B., López-Parra, V., López‐Franco, Ó., Muñoz‐García, B., Fernández‐Vizarra, P., Ortega, L. M., Egido, J., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.173781 · Cited by 125
Self-citationVallejo, S., Rosas, E. P., Romacho, T., Villalobos, L. A., Peiró, C., & Sánchez‐Ferrer, C. F. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0158-z · Cited by 125
Soetikno, V., Sari, F. R., Sukumaran, V., Lakshmanan, A. P., Harima, M., Suzuki, K., Kawachi, H., & Watanabe, K. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.04.013 · Cited by 124
Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation
Salmi, M., & Jalkanen, S. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7418 · Cited by 123
Interleukin‐18 and diabetic nephropathy: A review
Yaribeygi, H., Atkin, S. L., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27427 · Cited by 123
FcR-Bearing Myeloid Cells Are Responsible for Triggering Murine Lupus Nephritis
Bergtold, A., Gavhane, A., D’Agati, V. D., Madaio, M. P., & Clynes, R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7287 · Cited by 122
Kang, Y. S., Lee, M., Song, H. K., Ko, G. J., Kwon, O. S., Lim, T. K., Kim, S. H., Han, S. Y., Han, K. H., Lee, J. E., et al. (2010) · Kidney International · doi:10.1038/ki.2010.263 · Cited by 122
Yaribeygi, H., Mohammadi, M. T., Rezaee, R., & Sahebkar, A. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26806 · Cited by 118
Darisipudi, M. N., Kulkarni, O. P., Sayyed, S. G., Ryu, M., Migliorini, A., Sagrinati, C., Parente, E., Vater, A., Eulberg, D., Klußmann, S., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.004 · Cited by 116
Lavoz, C., Matus, Y. S., Orejudo, M., Carpio, J. D., Droguett, A., Egido, J., Mezzano, S. A., & Ruiz‐Ortega, M. (2019) · Kidney International · doi:10.1016/j.kint.2018.12.031 · Cited by 116
Self-citationYang, H. Y., Xu, W., Zhou, Z., Liu, J., Li, X., Chen, L., Weng, J., & Yu, Z. (2015) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0035-1545345 · Cited by 115
Increased expression of selectins in kidneys of patients with diabetic nephropathy
Hirata, K., Shikata, K., Matsuda, M., Akiyama, K., Sugimoto, H., Kushiro, M., & Makino, H. (1998) · Diabetologia · doi:10.1007/s001250050888 · Cited by 114
López‐Franco, Ó., Suzuki, Y., Sanjuán, G., Blanco, J., Hernández-Vargas, P., Yo, Y., Kopp, J. B., Egido, J., & Gómez‐Guerrero, C. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64425-2 · Cited by 112
Self-citationBanes, A. K., Shaw, S., Jenkins, J., Redd, H., Amiri, F., Pollock, D. M., & Marrero, M. B. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00163.2003 · Cited by 112
Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats
Moriwaki, Y., Inokuchi, T., Yamamoto, A., Ka, T., Tsutsumi, Z., Takahashi, S., & Yamamoto, T. (2007) · Acta Diabetologica · doi:10.1007/s00592-007-0007-6 · Cited by 110
The MIF Receptor CD74 in Diabetic Podocyte Injury
Sánchez-Niño, M. D., Sanz, A. B., Ihalmo, P., Lassila, M., Holthöfer, H., Mezzano, S. A., Aros, C., Groop, P., Saleem, M. A., Mathieson, P. W., et al. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008020194 · Cited by 110
Self-citationThe role of interleukin-17A in the pathogenesis of kidney diseases
Cortvrindt, C., Speeckaert, R., Moerman, A., Delanghe, J., & Speeckaert, M. M. (2017) · Pathology · doi:10.1016/j.pathol.2017.01.003 · Cited by 110
Glomerular VEGF resistance induced by PKCδ/SHP‐1 activation and contribution to diabetic nephropathy
Mima, A., Kitada, M., Geraldes, P., Li, Q., Matsumoto, M., Mizutani, K., Qi, W., Li, C., Leitges, M., Rask‐Madsen, C., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-202994 · Cited by 104
Dendritic Cells and Macrophages: Sentinels in the Kidney
Weisheit, C. K., Engel, D. R., & Kurts, C. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07100714 · Cited by 103
Lázaro, I., Oguiza, A., Recio, C., Mallavia, B., Madrigal‐Matute, J., Blanco, J., Egido, J., Martín-Ventura, J. L., & Gómez‐Guerrero, C. (2015) · Diabetes · doi:10.2337/db14-1926 · Cited by 103
Self-citationPodocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice
Zhang, H., Nair, V., Saha, J., Atkins, K. B., Hodgin, J. B., Saunders, T. L., Myers, M. G., Werner, T., Kretzler, M., & Brosius, F. C. (2017) · Kidney International · doi:10.1016/j.kint.2017.03.027 · Cited by 101
Wang, D., Jin, M., Zhao, X., Zhao, T., Lin, W., He, Z.-L., Fan, M., Jin, W., Zhou, J., Jin, L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1696-9 · Cited by 101
Lin, J., Glynn, R. J., Rifai, N., Manson, J. E., Ridker, P. M., Nathan, D. M., & Schaumberg, D. A. (2008) · Diabetes Care · doi:10.2337/dc08-0277 · Cited by 98
IL-1 Inhibition and Vascular Function in CKD
Nowak, K. L., Chonchol, M., Ikizler, T. A., Farmer‐Bailey, H., Salas, N., Chaudhry, R., Wang, W., Smits, G., Tengesdal, I. W., Dinarello, C. A., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040453 · Cited by 97
ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice
Tesch, G. H., Ma, F. Y., Han, Y., Liles, J. T., Breckenridge, D. G., & Nikolic‐Paterson, D. J. (2015) · Diabetes · doi:10.2337/db15-0384 · Cited by 95
Renal Protective Effects of Toll-like Receptor 4 Signaling Blockade in Type 2 Diabetic Mice
Cha, J. J., Hyun, Y. Y., Lee, M. H., Kim, J. E., Nam, D. H., Song, H. K., Kang, Y. S., Lee, J. E., Kim, H. W., Han, J., et al. (2013) · Endocrinology · doi:10.1210/en.2012-2080 · Cited by 95
Herder, C., Kolb, H., Köenig, W., Haastert, B., Müller-Scholze, S., Rathmann, W., Holle, R., Thorand, B., & Wichmann, H. ‐. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1474 · Cited by 95
Wang, S., Zhao, X., Yang, S., Chen, B., & Shi, J. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.10.012 · Cited by 95
Knockdown of NLRP3 alleviates high glucose or TGFB1-induced EMT in human renal tubular cells
Song, S., Qiu, D., Luo, F., Wei, J., Wu, M. T., Wu, H., Du, C., Du, Y., Ren, Y., Chen, N., et al. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0069 · Cited by 91
Chiarelli, F., Cipollone, F., Mohn, A., Marini, M., Iezzi, A., Fazia, M. L., Tumini, S., Cesare, D. D., Pomilio, M., Pierdomenico, S. D., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1829 · Cited by 90
Sullivan, T., Miao, Z., Dairaghi, D. J., Krasinski, A., Wang, Y., Zhao, B. N., Baumgart, T., Ertl, L. S., Pennell, A. M. K., Seitz, L., et al. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00316.2013 · Cited by 90
Macrophage Cyclooxygenase-2 Protects Against Development of Diabetic Nephropathy
Wang, X., Yao, B., Wang, Y., Fan, X., Wang, S., Niu, A., Yang, H., Fogo, A. B., Zhang, M., & Harris, R. C. (2016) · Diabetes · doi:10.2337/db16-0773 · Cited by 90
Enhanced Acute-Phase Response and Oxidative Stress in Older Adults with Type II Diabetes
Arnalich, F., Hernánz, Á., López-Maderuelo, D., Peña, J., Camacho, J., Madero, R., Vázquez, J., & Montiel, C. (2000) · Hormone and Metabolic Research · doi:10.1055/s-2007-978662 · Cited by 89
Miyauchi, K., Takiyama, Y., Honjo, J., Tateno, M., & Haneda, M. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.11.018 · Cited by 88
Serum Inflammatory and Immune Mediators Are Elevated in Early Stage Diabetic Nephropathy.
Perlman, A. S., Chevalier, J. M., Wilkinson, P. F., Liu, H., Parker, T. S., Levine, D. M., Sloan, B., Gong, A., Sherman, R. L., & Farrell, F. X. (2015) · PubMed · Cited by 88
Kolati, S. R., Kasala, E. R., Bodduluru, L. N., Mahareddy, J. R., Uppulapu, S. K., Gogoi, R., Barua, C. C., & Lahkar, M. (2015) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2015.01.019 · Cited by 87
DiPetrillo, K., & Gesek, F. A. (2004) · American Journal of Nephrology · doi:10.1159/000079121 · Cited by 87
Toll-like receptors: sensing and reacting to diabetic injury in the kidney
Lin, M., & Tang, S. C. W. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft446 · Cited by 87
Zhang, F., Wang, C., Wen, X., Chen, Y., Mao, R., Cui, D., Li, L., Liu, J., Chen, Y., Cheng, J., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15250 · Cited by 84
Liu, W., Zhang, X., Liu, P., Shen, X., Lan, T., Li, W., Jiang, Q. L., Xie, X., & Huang, H. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.04.033 · Cited by 82
Soedamah‐Muthu, S. S., Chaturvedi, N., Schalkwijk, C. G., Stehouwer, C. D. A., Ebeling, P., & Fuller, J. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.06.005 · Cited by 82
Lim, A. K. H., Ma, F. Y., Nikolic‐Paterson, D. J., Kitching, A. R., Thomas, M. C., & Tesch, G. H. (2010) · Diabetologia · doi:10.1007/s00125-010-1757-1 · Cited by 82
Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes
Lei, Y., Devarapu, S. K., Motrapu, M., Cohen, C. D., Lindenmeyer, M. T., Moll, S., Kumar, S. V. R., & Anders, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01223 · Cited by 82
Microinflammation in the pathogenesis of diabetic nephropathy
Shikata, K., & Makino, H. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12050 · Cited by 81
McKie, E., Reid, J. L., Mistry, P. C., DeWall, S. L., Abberley, L., Ambery, P., & Extremera, B. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150018 · Cited by 80
Role of the TNF pathway in the progression of diabetic nephropathy in KK-Aymice
Omote, K., Gohda, T., Murakoshi, M., Sasaki, Y., Kazuno, S., Fujimura, T., Ishizaka, M., Sonoda, Y., & Tomino, Y. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00509.2013 · Cited by 79
Diet‐induced Renal Changes in Zucker Rats Are Ameliorated by the Superoxide Dismutase Mimetic TEMPOL
Ebenezer, P. J., Mariappan, N., Elks, C. M., Haque, M., & Francis, J. (2009) · Obesity · doi:10.1038/oby.2009.137 · Cited by 77
Ninčević, V., Kolarić, T. O., Roguljić, H., Kizivat, T., Smolić, M., & Bilić-Čurčić, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235831 · Cited by 77
Ryba-Stanisławowska, M. E., Skrzypkowska, M. W., Myśliwiec, M., & Myśliwska, J. M. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.01.024 · Cited by 76
PI3Kinases in Diabetes Mellitus and Its Related Complications
Maffei, A., Lembo, G., & Carnevale, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124098 · Cited by 75
End-stage renal disease and survival in people with diabetes: a national database linkage study
Bell, S., Fletcher, E. H., Brady, I., Looker, H. C., Levin, D., Joss, N., Traynor, J. P., Metcalfe, W., Conway, B. R., Livingstone, S. J., et al. (2014) · QJM · doi:10.1093/qjmed/hcu170 · Cited by 74
Heme Oxygenase-1 Dysregulates Macrophage Polarization and the Immune Response to Helicobacter pylori
Gobert, A. P., Verriere, T. G., Asim, M., Barry, D. P., Piazuelo, M. B., de Sablet, T., Delgado, A. G., Bravo, L. E., Correa, P., Peek, R. M., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401075 · Cited by 74
The Role of MIF in Type 1 and Type 2 Diabetes Mellitus
Sánchez-Zamora, Y. I., & Rodríguez‐Sosa, M. (2014) · Journal of Diabetes Research · doi:10.1155/2014/804519 · Cited by 73
Clinical value of inflammatory urinary biomarkers in overt diabetic nephropathy: A prospective study
Verhave, J. C., Bouchard, J., Goupil, R., Pichette, V., Brachemi, S., Madore, F., & Troyanov, S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.07.006 · Cited by 72
Sumagin, R., & Sarelius, I. H. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00248.2006 · Cited by 72
Yılmaz, M. İ., Carrero, J. J., Martı́n-Ventura, J. L., Sönmez, A., Sağlam, M., Celık, T., Yaman, H., Yenicesu, M., Eyileten, T., Moreno, J. A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01110210 · Cited by 72
Self-citationYin, Q., Zhang, R., Li, L., Wang, Y.-T., Liu, J., Zhang, J., Bai, L., Cheng, J., Fu, P., & Liu, F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.730564 · Cited by 72
Recio, C., Oguiza, A., Lázaro, I., Mallavia, B., Egido, J., & Gómez‐Guerrero, C. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304144 · Cited by 70
Self-citationStahel, M., Becker, M., Graf, N., & Michels, S. (2015) · Retina · doi:10.1097/iae.0000000000000701 · Cited by 68
Role of Nuclear Factor Erythroid 2-Related Factor 2 in Diabetic Nephropathy
Cui, W., Min, X., Xu, X., Du, B., & Luo, P. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3797802 · Cited by 68
Cited by
Targeting inflammation to treat diabetic kidney disease: the road to 2030
Rayego-Mateos, S., Rodrigues-Diez, R. R., Fernandez-Fernandez, B., Mora-Fernández, C., Marchant, V., Donate-Correa, J., Navarro-González, J. F., Ortiz, A., & Ruiz-Ortega, M. (2023) · Kidney International · doi:10.1016/j.kint.2022.10.030 · Cited by 366
Self-citationZhao, C., Pu, Z., Gao, J., Liu, C., Xing, J., Lang, W., Chen, J., Yuan, C., & Zhou, C. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c05595 · Cited by 26
Gao, R.-H., Liu, B., Yang, Y., Ran, R., Zhou, Y., & Liu, S.-M. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s409410 · Cited by 17
Zhu, H.-M., Liu, N., Sun, D.-X., & Luo, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202298 · Cited by 12
“There is a growing body of research that points to oxidative stress and inflammation as the primary contributors to the development of DN (3, 42).”
Background
Metadata
- Authors
- Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-27
- Volume
- 21
- Issue
- 11
- Pages
- 3798
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3032465091
- Cited by
- 334
- References
- 305
- FWCI
- 19.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.